Prognostic implications of estrogen receptor 1 and vascular endothelial growth factor A expression in primary gallbladder carcinoma

Table 3 Univariate analysis of prognostic factors associated with overall survival in patients with gallbladder carcinoma

Risk factor	Survival time(month) (mean ± SE)	P-value (Log-rank test)
Gender		0.682
Male	23.24 ± 4.09
Female	21.97 ± 1.72
Age (yr)		0.015
≤ 55	26.34 ± 2.71
> 55	18.77 ± 1.71
Gallstones		0.068
Present	17.69 ± 2.06
Absent	23.96 ± 2.02
TNM stage		0.007
II	27.16 ± 2.77
III/IV	18.59 ± 1.74
Differentiation		0.685
Well	23.19 ± 2.94
Moderate/poor	21.65 ± 1.86
ER1 level		0.053
High	19.81 ± 1.79
Low	25.85 ± 2.86
VEGF-A level		0.155
High	20.35 ± 1.87
Low	25.65 ± 2.86
ER1 combined with VEGF-A		0.007
+/+	16.30 ± 1.87
+/-, -/+, -/-	24.97 ± 2.09

ER1: Estrogen receptor 1; VEGF-A: Vascular endothelial growth factor A; TNM: Tumor node metastasis; +/+: High ER1 expression and high VEGF-A expression; +/-: High ER1 expression and low VEGF-A expression; -/+: Low ER1 expression and high VEGF-A expression; -/-: Low ER1 expression and low VEGF-A expression.